- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01477125
Working Memory Training in Adults With ADHD
September 2, 2020 updated by: Ylva Ginsberg, MD, PhD, Karolinska Institutet
Computerised Working Memory Training in Adults With ADHD: A Randomised Controlled Trial
The purpose of this study is to evaluate whether computerised working memory training improves cognitive performance, ADHD symptoms, psychosocial functioning and quality of life in adults with ADHD, from psychiatric outpatient clinics (N=100) as well as from a high-security prison facility (N=50).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The primary aim is to evaluate whether 5 weeks of computerised working memory training improves working memory capacity.
Secondary aims are to explore whether improvements in working memory capacity will be transferred to improvements in learning abilities and fluid intelligence.
Also, far transfer effects on executive functioning, ADHD symptoms, psychosocial functioning and quality of life will be explored.
Finally, it will also be assessed to what extent improvements gained from 5 weeks of working memory training will be maintained 3 and 6 months post-study, respectively.
Study Type
Interventional
Enrollment (Actual)
102
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Stockholm, Sweden, 171 77
- Karolinska Institutet
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Confirmed ADHD according to DSM-IV criteria; ADHD combined type, ADHD inattentive type or ADHD UNS, primarily inattentive type.
- Unmedicated for ADHD during the course of the trial, or being under stable ADHD medication for at least one month at baseline visit and without any planned changes in medication until post-study assessments have taken place.
Exclusion Criteria:
- Previous participation in computerised working memory training (completed training).
- Any psychiatric disorder that in the judgment of the investigator, may interfere with study participation and/or study assessments, also including current substance abuse.
- Participation in psychological treatment addressing ADHD during the course of the 5-week training period (psychoeducation is accepted).
- Initiation of psychological treatment for coexistent disorders during the course of the study (treatment already ongoing at baseline visit is accepted if there are no planned changes during the 5-week training period).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Flex working memory training
30-40 minutes of working memory training, 5 days a week for 5 weeks
|
30-40 minutes of working memory training, 5 days a week for 5 weeks
|
|
Placebo Comparator: Control version of Flex
30-40 minutes of training with a control version of Flex, 5 days a week for 5 weeks.
|
30-40 minutes of working memory training, 5 days a week for 5 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in a composite measure of working memory capacity
Time Frame: Baseline and 7 weeks
|
The composite measure of working memory capacity comprises the sum score of:
|
Baseline and 7 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in a composite measure of working memory capacity
Time Frame: Baseline and 31 weeks
|
The composite measure of working memory capacity will be assessed in a 6-month follow-up conducted at week 31 post-baseline, equivalent to week 24 post-intervention, to assess retention of any training-related improvements.
|
Baseline and 31 weeks
|
|
Change in Digit Span Forwards/Backwards score
Time Frame: Baseline, 7 and 31 weeks
|
Evaluating changes in both Digit Span forwards and backwards scores, as measures of simple verbal working memory capacity.
|
Baseline, 7 and 31 weeks
|
|
Change in Span Board Forwards/Backwards score
Time Frame: Baseline, 7 and 31 weeks
|
Evaluating changes in both Span Board forwards and backwards scores as measures of simple visuo-spatial working memory capacity.
|
Baseline, 7 and 31 weeks
|
|
Change in Arithmetics score
Time Frame: Baseline, 7 and 31 weeks
|
Evaluating change in Arithmetics score, as a measure of complex verbal working memory capacity as well as of mathematics ability.
|
Baseline, 7 and 31 weeks
|
|
Change in Spatial Working Memory score
Time Frame: Baseline, 7 and 31 weeks
|
Evaluating change in Spatial Working Memory score as a measure of complex visuo-spatial working memory capacity.
|
Baseline, 7 and 31 weeks
|
|
Change in Qbtest scores
Time Frame: Baseline, 7 and 31 weeks
|
Evaluating changes in Qbtest, a computerised CPT that in addition to measuring inattention and impulsivity also captures motor activity by an IR device during performance of the CPT.
|
Baseline, 7 and 31 weeks
|
|
Change in Raven´s Standard Progressive Matrices score
Time Frame: Baseline, 7 and 31 weeks
|
Evaluating change in score of a short version of Raven´s Standard Progressive Matrices, as a measure of fluid intelligence.
|
Baseline, 7 and 31 weeks
|
|
Change in Adult ADHD Self-Report Scale (ASRS-v1.1) Symptom Checklist
Time Frame: Baseline, 7, 19, and 31 weeks
|
Evaluating changes in ADHD symptoms by self-reported and informant-reported (significant other) versions of ASRS-v1.1, conducted at baseline, post-intervention, at 3-month and 6-month follow-up.
|
Baseline, 7, 19, and 31 weeks
|
|
Change in Sheehan Disability Scale (SDS)
Time Frame: Baseline, 7, 19, and 31 weeks
|
Evaluating changes in psychosocial functioning by the self-reported SDS conducted at baseline, post-intervention, at 3-month and 6-month follow-up.
|
Baseline, 7, 19, and 31 weeks
|
|
Change in EuroQol- 5 Dimensions (EQ-5D) questionnaire
Time Frame: Baseline, 7, 19, and 31 weeks
|
Evaluating change in health-related quality of life by the self-reported generic QoL questionnaire EQ-5D, conducted at baseline, post-intervention, at 3-month and 6-month follow-up.
|
Baseline, 7, 19, and 31 weeks
|
|
Change in Adult ADHD Quality of Life Measure (AAQoL)
Time Frame: Baseline, 7, 19, and 31 weeks
|
Evaluating change in health-related quality of life by the self-reported ADHD specific QoL measure AAQoL, conducted at baseline, post-intervention, at 3-month and 6-month follow-up.
|
Baseline, 7, 19, and 31 weeks
|
|
Montgomery Åsberg Depression Rating Scale-Self report (MADRS-S)
Time Frame: Baseline and 7 weeks
|
Evaluating if depressive symptoms during the training period, as measured by the self-reported MADRS-S will influence adherence to and results of the working memory training.
|
Baseline and 7 weeks
|
|
Adverse events
Time Frame: Baseline and 7 weeks
|
All adverse events that occurred during the course of the 5-week intervention will be collected as part of the post-intervention assessments at week 7.
|
Baseline and 7 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Ylva Ginsberg, MD, PhD, Karolinska Institutet
- Study Director: Henrik Larsson, PhD, Karolinska Institutet
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2013
Primary Completion (Actual)
December 15, 2017
Study Completion (Actual)
June 15, 2018
Study Registration Dates
First Submitted
November 15, 2011
First Submitted That Met QC Criteria
November 18, 2011
First Posted (Estimate)
November 22, 2011
Study Record Updates
Last Update Posted (Actual)
September 3, 2020
Last Update Submitted That Met QC Criteria
September 2, 2020
Last Verified
September 1, 2020
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- X002
- DAT-NSP (Other Identifier: Karolinska Institutet)
- DAT-KV (Other Identifier: Karolinska Institutet)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Attention Deficit Hyperactivity Disorder
-
King's College LondonActive, not recruitingAttention-Deficit Hyperactivity Disorder | Attention-Deficit Hyperactivity Disorder SymptomsUnited Kingdom
-
Cingulate TherapeuticsSuspendedPhase 3 Efficacy and Safety Laboratory Classroom Study in Pediatrics (6-12) With ADHD Using CTx-1301ADHD | Attention Deficit Hyperactivity Disorder | Attention Deficit Disorder With Hyperactivity | ADHD - Combined Type | Attention Deficit Hyperactivity Disorder Combined | Attention Deficit Hyper Activity | Attention-deficit HyperactivityUnited States
-
Ornit CohenUnknownAttention Deficit Hyperactivity Disorder | Attention Deficit Disorder With Hyperactivity | Attention Deficit Disorder | Attention Deficit Disorders With Hyperactivity | Attention Deficit Hyperactivity DisordersIsrael
-
Qbtech ABEnrolling by invitationAttention Deficit Disorder With Hyperactivity (ADHD) | Attention Deficit Disorder (ADD)United States
-
Cingulate TherapeuticsPremier Research Group plcCompletedADHD | Attention Deficit Hyperactivity Disorder | ADHD - Combined Type | Attention Deficit Hyperactivity Disorder Combined | Attention Deficit Hyper Activity | Attention-deficit HyperactivityUnited States
-
University of Texas at AustinRecruitingAttention Deficit Hyperactivity DisorderUnited States
-
Rutgers, The State University of New JerseyNational Institute of Mental Health (NIMH); Louisiana State University Health...Recruiting
-
Probi ABNot yet recruitingAttention Deficit Hyperactivity Disorder (ADHD)China
-
University of IcelandNot yet recruitingAttention-Deficit/Hyperactivity Disorder (ADHD)
-
Qilu Hospital of Shandong UniversityNot yet recruitingAttention Deficit Hyperactivity Disorder (ADHD)
Clinical Trials on Flex working memory training
-
Wayne State UniversityRecruitingBehavior, HealthUnited States
-
University of GeorgiaRecruitingSchizophrenia | Schizo Affective DisorderUnited States
-
Milwaukee VA Medical CenterCompletedPosttraumatic Stress DisorderUnited States
-
KU LeuvenActive, not recruitingCerebral PalsyBelgium
-
Radboud University Medical CenterNetherlands Organisation for Scientific ResearchCompletedAttention Deficit Disorder With HyperactivityNetherlands
-
St. Jude Children's Research HospitalAmerican Cancer Society, Inc.CompletedAcute Lymphoblastic Leukemia | Brain TumorUnited States
-
Norwegian University of Science and TechnologyCompletedInfant, Very Low Birth WeightNorway
-
University of MichiganTerminated
-
University of WaterlooCompleted